Enanta Pharmaceuticals to Host Conference Call on May 6 at 4:30 p.m. E...

Your unfiltered news center. ®

The world you see depends upon the news you get. ®

HOME

ARTS

RSS

Today's Date: May 14, 2024

SilverCrest Reports First Quarter 2024 Financial Results • Tetra Tech Launched Its 2030 Vision at Its Inaugural Investor Day • Evan Williams Bourbon announces 2024 class of American-Made Heroes to be featured on bottles nationwide • Beachbody (BODi) Launches “Invest in Your BODi” Retail Shareholder Rewards Program • Indigenous Identity Fraud Summit: Distorting Truths, Erasing Heritage • Ventas Declares Second Quarter 2024 Dividend of $0.45 Per Common Share • Stonepeak and CHC Form Japanese Battery Energy Storage Platform • Mitsubishi Electric and Musashi Energy Solutions Sign Partnership and Co-Development Contract • CJF Bursary for BIPOC Student Journalists Awarded • California American Water Appoints Spencer Vartanian as Director of Operations for Monterey • Embark Behavioral Health Launches Summer T.I.M.E. Program for Adolescent Wellbeing • New CHOP Research Links Genetics, Environment and Health Disparities to Increased Stress and Mental Health Challenges During Ado • Nintendo News: Celebrate 35 Years of Game Boy With Super Mario Land and More Games, Now Available on Nintendo Switch Online! • Edgewell Personal Care's Banana Boat Named a Finalist in Nature Category of Fast Company's 2024 World Changing Ideas • Houston Schools and Organizations Named as Houston Schools That Inspire Inaugural Honorees by Good Reason Houston • Building more child care spaces for families in Manitoba • OLD PARR SCOTCH WHISKY AND BRAZILIAN FÚTBOL LEGEND ROBERTO CARLOS ARE OFFERING FANS A CHANCE TO WIN A TRIP TO MIAMI FOR T • Meijer Opens New Supercenter in Hillsdale • Verve Senior Living was named one of Canada's Best Managed Companies for the second year running • HUNDREDS OF PHYSICIANS AND MEDICAL PRACTITIONERS SET TO CONVENE AT THE 2024 ANNUAL CIRS CONFERENCE TO ADDRESS MOLD ILLNESS, WHIC

Enanta Pharmaceuticals to Host Conference Call on May 6 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Q

WATERTOWN, Mass. , April 29 /Businesswire/ - Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that it plans to report its financial results for its fiscal second quarter ended March 31, 2024, after the U.S. market closes on May 6, 2024. Enanta management will host a conference call at 4:30 p.m. ET to discuss these results and provide an update on Enanta’s business, including its research and development pipeline.

Conference Call and Webcast Information

The live webcast can be accessed under "Events & Presentations" in the investors section of Enanta’s website. To join by phone, participants can register for the call here. It is recommended that participants register a day in advance or at a minimum of 15 minutes before the call. Once registered, participants will receive an email with the dial-in information. The archived webcast will be available on Enanta’s website for approximately 30 days following the event.

About Enanta Pharmaceuticals, Inc.

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for virology and immunology indications. Enanta’s research and development programs are currently focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU) and the company has previously advanced clinical-stage compounds for SARS-CoV-2 (COVID-19) and chronic hepatitis B virus (HBV) infection.

Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis C virus infection (HCV) and is sold by AbbVie in numerous countries under the trade names MAVYRET^®(U.S.) and MAVIRET^®(ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit http://www.enanta.com for more information.